Unicycive Therapeutics UNCY Institutional Ownership

Updated Oct 10, 2026

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) had 80 institutional holders reporting a position on Form 13F for the quarter ended June 30, 2026.

• Together they owned 41.69% of the outstanding stock in Q2 2026, up from 39.25% a quarter earlier.
• Total shares held in UNCY rose 17.22% from Q1 2026; the number of holders rose 321.05% from Q2 2025.
• Among the 80 holders of Unicycive Therapeutics, 58 added to their positions, 12 reduced their stakes and 10 left their positions unchanged.
• In total, institutional investors held 11.61Mn shares of Unicycive Therapeutics at the end of Q2 2026, up 1.71Mn from the prior quarter and up 6.47Mn from a year earlier.
• As of June 30, 2026, the biggest holder of Unicycive Therapeutics was BlackRock, Inc. with 1.41Mn shares, or 5.07% of shares outstanding.
• The largest position increases in UNCY for Q2 2026 were by BlackRock, Inc. (+1.38Mn shares), Nantahala Capital Management, LLC (+462.25K shares), Marshall Wace, LLP (+392.92K shares), State Street Corp (+370.13K shares) and Geode Capital Management, LLC (+360.27K shares).
• The largest position reductions in UNCY for Q2 2026 were by Vivo Capital, LLC (-1.24Mn shares), Millennium Management LLC (-1.13Mn shares), Citadel Advisors LLC (-175.67K shares), BNP Paribas Financial Markets (-115.8K shares) and Morgan Stanley (-78.54K shares).
• Per Business Quant, the top 10 investors in UNCY for the quarter ended June 30, 2026 were BlackRock, Inc. (1.41Mn shares), Nantahala Capital Management, LLC (1.4Mn shares), Vanguard Capital Management LLC (1.07Mn shares), Octagon Capital Advisors LP (1Mn shares), Geode Capital Management, LLC (564.02K shares), Vivo Capital, LLC (550K shares), Marshall Wace, LLP (547.86K shares), Logos Global Management LP (473.56K shares), State Street Corp (450.16K shares) and Diametric Capital, LP (374.13K shares).